MARCH 22, 2019: According to the new policy, Cigna will review submissions for FDA-approved exoskeletons, including Indego, for use as a medical device by individuals with spinal cord injury on a case-by-case basis.
SEPTEMBER 20, 2018: Parker's next generation Indego Therapy device offers clinicians the ability to provide custom-tailored gait therapy programs to patients with spinal cord injury and stroke.
Evidence Based Development
Indego has been developed in close coordination with clinicians and patients. Although the benefits of Indego hold great promise for its use in therapy and at home, Parker is committed to providing the most usable and effective device, backed by substantial research. To that end, Parker has partnered with some of the world’s leading rehabilitation centers to establish a body of evidence that demonstrates its benefits. Learn more about Indego through our published and upcoming research.
Follow Indego on social media:
Looking for the City of Philadelphia's Indego™ bike share system?
Indego® is a registered trademark of Parker Hannifin Corporation. © 2020 Parker Hannifin Corporation
Parker Hannifin Corporation
Human Motion & Control
1390 E. Highland Rd.
Macedonia, OH U.S.A.
International: +44 1 442 458 036
1.844.846.3446
support.indego@parker.com